0A2V.IL

Sanofi | Cotação de Ações

Última atualização24/12/2024, 14:50:22

PreçoUS$ 48,29

Variação (dia)US$ 0,28 (0.58%)▲

Min. 52 Semanas--

Máx. 52 SemanasUS$ 52,77

Capitalização de mercado--

Endereço: 46, avenue de la Grande Arm e, Paris, 75017

Telefone: 33 1 53 77 40 00

Funcionários: 91.573

SANOFI SA SANOFI ADR REP 1 1/2 0A2V.IL

US$ 48,29

+ 0,2790,58%

24/12/2024 14:50:22

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 48,29

Valor de mercado--

AberturaUS$ 47,72

Preço máximo--

Preço mínimo--

VolumeUS$ 11

Fechamento anteriorUS$ 48,01

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Ações relacionadas

Novartis AG

0QLR.IL ▼0.00% | CHF 86,88

Sanofi

0O59.IL ▲0.54% | € 92,30

Pfizer Inc.

0Q1N.IL ▲0.40% | US$ 26,75

Bristol-Myers Squibb Company

0R1F.IL ▲0.41% | US$ 57,54

Amgen Inc.

0R0T.IL ▲3.00% | US$ 264,50

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.

Saiba mais sobre a brapi e nossa missão de fornecer informações confiáveis

Entenda a missão da brapi em fornecer informações estritamente informativas de fontes confiáveis. Valorizamos a transparência e a responsabilidade, incentivando investidores a buscar aconselhamento financeiro independente para decisões informadas.

Acesse a Documentação para uma compreensão detalhada da nossa plataforma

Explore a Documentação para uma compreensão detalhada de como utilizar efetivamente nossa plataforma para análise de investimentos. Oferecemos recursos abrangentes para orientar investidores, desde iniciantes até experientes, na navegação por nossa plataforma.